跳至主要内容
临床试验/NCT03744013
NCT03744013已完成不适用

A Post Market Prospective Study of FORTIVA® 1mm Porcine Dermis in Breast Reconstruction

RTI Surgical12 个研究点 分布在 2 个国家目标入组 87 人开始时间: 2019年5月7日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
RTI Surgical
入组人数
87
试验地点
12
主要终点
Safety of Fortiva® tissue matrix

研究概览

简要总结

This is a post market prospective, multi-center study of up to 100 subjects undergoing post-mastectomy breast reconstruction (50 Fortiva® 1mm perforated and 50 Fortiva® 1mm non-perforated) at up to 10 clinical study sites in Europe.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 100 Years(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • Female 18 years or older
  • A candidate for immediate breast reconstruction during post-skin sparing or nipple-sparing mastectomy (unilateral or bilateral)
  • Estimated life expectancy > 2 years
  • Able and willing to return for all scheduled and required study visits
  • Able to provide written informed consent for study participation
  • Able to read, understand and complete study questionnaires

排除标准

  • Any of the conditions listed in the approved labeling as contraindicated
  • Currently enrolled or plans to enroll in another clinical study that would affect the validity of the study
  • Any patient that per the physician's judgement is not a good candidate for this study

结局指标

主要结局

Safety of Fortiva® tissue matrix

时间窗: 24 months

Safety will be evaluated by assessing the incidence of device and/or procedure related adverse events.

Performance of Fortiva® tissue matrix

时间窗: 24 months

• Analysis of the subject's overall satisfaction with the breast reconstruction procedure will be assessed by obtaining subject's perception of the outcomes using the Breast-QTM - Reconstruction survey.

次要结局

未报告次要终点

研究者

发起方
RTI Surgical
申办方类型
Industry
责任方
Sponsor

研究点 (12)

Loading locations...

相似试验